News – Page 117 – Endpoints News

Kyowa Kirin divests China unit, prunes discovery and manufacturing work

9 months ago

23andMe board rejects Anne Wojcicki’s take-private plan, requests changes

9 months ago

PARP biotech backed by more than five pharmas closes after nine years

9 months ago

Galapagos pauses blood cancer CAR-T therapy trial due to one Parkinsonism event

9 months ago

Agios' late-stage Pyrukynd trial in kids with rare blood disorder misses primary endpoint

9 months ago

Former RayzeBio CEO quickly returns with new biotech; Amgen’s global research leader steps down

9 months ago

Exclusive: Ultragenyx secures first funds for Alzheimer's gene therapy spinout

9 months ago

Adaptimmune gets FDA accelerated approval for T cell receptor cell therapy in rare soft tissue cancer

9 months ago

Vertex says about 20 patients have started sickle cell therapy, cuts two rare disease programs

9 months ago

Vir's overhaul brings an end to most virology work — and a beginning with cancer

9 months ago

GSK scores expanded label for Jemperli in first-line endometrial cancer

9 months ago

Despite recent trial success, uniQure plans to cut 65% of staff

9 months ago

RSV market pressure leads to slower launch for Moderna's vaccine

9 months ago

Novartis sues FDA over approval of Entresto generic, following rejection of petition

9 months ago

Pfizer mulls facility sale; GSK penalized in South Korea for administrative breach

9 months ago

Blueprint ups Ayvakit guidance; Aurinia to advance autoimmune disease asset

9 months ago

Arbutus reduces headcount after axing HBV combo trial that features Imfinzi

9 months ago

Sanofi pours €1.3B into new insulin manufacturing plant in Frankfurt

9 months ago

Biogen CEO sees Alzheimer's drug on right path despite tiny sales, will keep biosimilars business

9 months ago

With $144M Series B, Outpace Bio beats funding goal for solid tumor cell therapies

9 months ago

AbbVie closes $8.7B Cerevel deal in bid to compete with Bristol Myers in schizophrenia

9 months ago

VC firm venBio secures $528M for ‘extremely selective’ fifth fund after recent IPOs, M&A exits

9 months ago

Updated: Jim Wilson to step down from gene therapy post at UPenn, will form two new companies

9 months ago

US sales for Merck KGaA’s Bavencio impacted by Padcev/Keytruda momentum in bladder cancer

9 months ago

First page Previous page 114 115 116117118 119 120 Next page Last page